Researchers use matched human embryonic stem cell lines to understand the perturbed developmental mechanisms which lead to heart defects in Down's Syndrome patients.
The implementation of mass cytometry analysis to the reprogramming process has illuminated the early chaotic stages of reprogramming and has uncovered essential new pathways controlling the process.
Researchers combine multiple stem/progenitor types to generate miniature functional organ “buds” which may be useful in developmental and disease modelling, and in the future, tissue replacement.
Gene editing technology, combined with iPSC generation and a clinically relevant differentiation strategy combine to offer a new treatment for a blood borne genetic disease